TRYPTAMINE THERAPEUTICS

ASX Release **18 November 2025**

Second patient enrolled in TRP-8803 trial to treat Binge Eating Disorder with first patient to be dosed in two weeks

- **Second patient successfully enrolled in world first clinical trial evaluating TRP-8803 (IV-infused psilocin) for the treatment of Binge Eating Disorder (BED)**
- **First patient scheduled to be dosed on 1 December 2025, marking the first clinical administration of TRP-8803 in a BED population – Top line results on track for Q1 CY26**
- **Additional participants currently being screened and further enrolments anticipated near term**

Melbourne, Australia – Tryptamine Therapeutics Limited ('**Tryp**', '**TYP**' or the '**Company**') (**ASX: TYP**), a clinical-stage biotechnology company, is pleased to advise that Swinburne University's clinical trial team has completed patient enrolment of a second patient in the Company's trial to treat Binge Eating Disorder (BED) using TRP-8803 (IV-infused psilocin). The dosing of the first patient has been scheduled for 1 December 2025.

This world-first trial will recruit a total of 12 patients suffering from BED, in two six-person cohorts. Each cohort will be administered two doses of TRP-8803, 14 days apart in concert with supportive therapy. The first cohort will receive a mid-range dose and the second cohort will be administered a higher-range dose.

Second patient now enrolled

The latest enrolment followed extensive screening and face-to-face interviews with the Swinburne clinical team to ensure applicability, in accordance with the highest standards of patient safety and research ethics.

A four-week baseline assessment for the patient has now commenced, which includes measurement of binge eating behaviour, Body Mass Index (BMI) and vital signs and comprehensive psychological and safety evaluations. Laboratory testing, including blood chemistry, haematology, serology and urinalysis, as well as neuropsychiatric assessments will also be undertaken to ensure sufficient patient data.

Tryp continues to work alongside Swinburne to advance patient recruitment. Additional prospective patients are currently undergoing screening, with further enrolments expected shortly.

The Company is pleased to advise it has secured recruitment support from Butterfly Foundation in relation to its clinical trial. The group is Australia's leading charity dedicated to supporting people affected by eating disorders and body image concerns, as well as their families and carers. Butterfly provides Australia's only National Helpline for eating disorders, counselling, recovery programs and advocacy initiatives designed to improve access to care and reduce stigma. The organisation also plays a key role in community education and early intervention, working alongside clinicians, researchers and policymakers to drive improved treatment pathways and health outcomes.

Butterfly Foundation has provided community-based support to assist with awareness, patient engagement and broader education surrounding Binge Eating Disorder since its inclusion in the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) in 2013. In recent weeks, Butterfly has also assisted with Tryp's patient recruitment initiatives for the BED trial. Butterfly's support reflects the growing recognition of BED as a serious and widespread mental health condition requiring specialised clinical attention and new therapeutic approaches.

For personal use only

For personal use only

First patient dosing

Tryp advises it has scheduled first patient dosing for 1 December 2025. This marks a major development for the Company and is the first time TRP-8803 will be administered and clinically evaluated in a BED population.

This initial dosing will be undertaken as part of the first cohort, which is receiving a mid-range dose of TRP-8803. The administration will be followed by supportive therapy, as well as a second dose of TRP-8803 spaced 14 days from the initial infusion – this second administration is scheduled for 15 December 2025.

First patient dosing follows completion of all baseline work and will be closely followed by additional patients to ensure top-line results in Q1 CY26.

Commentary:

Butterfly Foundation Chief Executive Officer, Dr Jim Hungerford, said: *"Binge Eating Disorder is one of the most common eating disorders, impacting more than 230,000 people in Australia in any given year. Despite this, Binge Eating Disorder is often shrouded in stigma and shame, and many people are unable to access the treatment and support they need. Further research into Binge Eating Disorder and additional treatment options is critical to breaking down stigma and encouraging help-seeking, and we look forward to seeing the results of this world-first clinical trial."*

Tryp Chief Executive Officer, Jason Carroll, said: *"Advancing additional recruitment initiatives and moving towards first patient dosing marks a pivotal milestone for Tryp and for the field of psychedelic-assisted treatment. Importantly, the Company now has a scheduled date the first time TRP-8803 will be evaluated in a patient with Binge Eating Disorder. The support of Butterfly Foundation will also be instrumental in helping raise awareness and connect with patients who may benefit from participating in this study. Their support underscores the importance of developing safe, evidence-based therapeutic pathways for people living with BED.*

"We look forward to commencing first patient dosing on 1 December, alongside additional patient enrolment and reporting top-line results in Q1 2026."

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

Investor & media contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Tryptamine Therapeutics Limited

Tryp is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome.

Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.tryptherapeutics.com.

Register for updates

The Company encourages investors to register their details with Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done by:

- *Go to investor.automic.com.au*
- *If you're an existing user, log in with your username and password*
- *If you're a new user, click 'register', select 'Tryptamine Therapeutics Limited'. Enter your Holding Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.*
- *Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and select 'electronic only'*

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For personal use only